Evidence map›Paper›PMID 40681758›Full record

ArticleJournal of cancer research and clinical oncology2025

Effects of Maackia amurensis seed lectin (MASL) on OSCC cell morphology, PDPN expression, growth, and motility in a phase 1 clinical trial.

Ariel C Yin, Cayla J Holdcraft, Tyler J Helmig, Eamonn J Brace, David I Suster, Alan J Shienbaum, Dylan Roden, Evelyne Kalyoussef, Ghayoour Mir, Eugenio Capitle and 8 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04188665 (Using Maackia Amurensis Seed Lectin to Target the Podoplanin Receptor as a Functionally Relevant Biomarker to Inhibit the Growth of Oral Squamous Cell Carcinoma and Precancerous Lesions), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04188665 early_phase1completednot on this map

Using Maackia Amurensis Seed Lectin to Target the Podoplanin Receptor as a Functionally Relevant Biomarker to Inhibit the Growth of Oral Squamous Cell Carcinoma and Precancerous Lesions

TypeinterventionalSponsorRowan UniversityRan2021 to 2025Enrolled18ConditionsSquamous Cell Carcinoma of Head and NeckArmsMASL, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Journal of international medical research · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ariel C YinCell and Molecular Biology, Rowan Virtua SOM, Rowan University, 2 Medical Center Dr., Stratford, NJ, 08084, USA.
Cayla J HoldcraftCell and Molecular Biology, Rowan Virtua SOM, Rowan University, 2 Medical Center Dr., Stratford, NJ, 08084, USA.
Tyler J HelmigCell and Molecular Biology, Rowan Virtua SOM, Rowan University, 2 Medical Center Dr., Stratford, NJ, 08084, USA.
Eamonn J BraceCell and Molecular Biology, Rowan Virtua SOM, Rowan University, 2 Medical Center Dr., Stratford, NJ, 08084, USA.
David I SusterRutgers New Jersey Medical School, 185 S Orange Ave, Newark, NJ, 07103, USA.
Alan J ShienbaumKeystone Pathology Associates, 781 Keystone Industrial Park Rd, Dunmore, PA, 18512, USA.
Dylan RodenRutgers New Jersey Medical School, 185 S Orange Ave, Newark, NJ, 07103, USA.
Evelyne KalyoussefRutgers New Jersey Medical School, 185 S Orange Ave, Newark, NJ, 07103, USA.
Ghayoour MirRutgers New Jersey Medical School, 185 S Orange Ave, Newark, NJ, 07103, USA.
Eugenio CapitleRutgers New Jersey Medical School, 185 S Orange Ave, Newark, NJ, 07103, USA.
Soly BaredesRutgers New Jersey Medical School, 185 S Orange Ave, Newark, NJ, 07103, USA.
Rabie M ShantiDiagnostic Sciences, Rutgers School of Dental Medicine, 110 Bergen St,, Newark, NJ, 07103, USA.
Mika K KanekoDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Yukinari KatoDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Hisataka KobayashiMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Aki FurusawaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Mahnaz FatahzadehDiagnostic Sciences, Rutgers School of Dental Medicine, 110 Bergen St,, Newark, NJ, 07103, USA. fatahza@sdm.rutgers.edu.
Gary S GoldbergCell and Molecular Biology, Rowan Virtua SOM, Rowan University, 2 Medical Center Dr., Stratford, NJ, 08084, USA. gary.goldberg@rowan.edu.

Funding

Targeting OSCC cells with a lozenge to treat oral cancerR41CA268160 · NCI · SENTRIMED, INC. · PI GOLDBERG, GARY · 2022 to 2023
$604k
Cadherins, contact normalization, and targeting podoplanin to treat oral cancerR15CA271044 · NCI · ROWAN UNIVERSITY SCHOOL/OSTEOPATHIC MED · PI GOLDBERG, GARY S · 2022 to 2022
$483k
Targeting Podoplanin to Prevent and Combat Oral CancerR15CA235347 · NCI · ROWAN UNIVERSITY SCHOOL/OSTEOPATHIC MED · PI GOLDBERG, GARY S · 2019 to 2019
$480k
Intramural Research Program of the National Institutes of Health, National Cancer Institute ZIA BC 011513Japan Agency for Medical Research and Development JP24am0521010 and JP24ama121008NCI NIH HHS R15 CA235347NCI NIH HHS R15 CA271044NCI NIH HHS R41 CA268160New Jersey Health Foundation PC78-24NIHNIH HHS 1R15CA271044-01 and 1R41CA268160-01A1
6 · The paper itself

Abstract

backgroundPodoplanin (PDPN) has emerged as a functionally relevant biomarker and chemotherapeutic target expressed by OSCC cells. PDPN signaling can directly increase tumor cell invasion and metastasis, and also inhibit host lymphocyte activation and immune response. Accordingly, antibodies and Maackia amurensis seed lectin (MASL) can target the PDPN receptor to inhibit OSCC cell migration and viability. However, the effects of MASL on OSCC cells in oral cancer patients has not yet been reported.

methodsWe conducted a Phase 1 human clinical trial to examine the effects of a single 100 mg oral dose of MASL on OSCC cell morphology, PDPN expression, and immune cell infiltration in lesions in oral cancer patients. We also examined the effects of MASL on the PDPN expression, motility, and viability of cells cultured from these patient lesions. In addition, we examined the ability of antibodies to target PDPN and kill OSCC cells by near-infrared photoimmunotherapy.

resultsMASL administration was found to be safe and did not produce any adverse effects in any patients. While this single dose did not affect OSCC cell morphology in lesions in situ, it did appear to increase lymphocyte infiltration into tumor fields in one patient by over 5 fold (p < 0.01). In addition, MASL inhibited the growth and motility of all OSCC cells cultured from these patient lesions in a dose responsive manner in vitro (p < 0.05 in all cases) We also report that antibodies can target PDPN on OSCC cells obtained from these patients to destroy them by near-infrared photoimmunotherapy (NIR-PIT).

conclusionThese results suggest that protocols using MASL and photoimmunotherapies that target PDPN can be developed to effectively treat OSCC lesions in oral cancer patients.

Indexed as

Carcinoma, Squamous CellMembrane GlycoproteinsMouth NeoplasmsPlant LectinsAdultAgedCell MovementCell ProliferationFemaleHumansMaleMiddle AgedPodoplaninSeedsMembrane GlycoproteinsPDPN protein, humanPlant LectinsPodoplaninKeywords: Maackia amurensis seed lectinMASLNear-infrared photoimmunotherapyNIR-PITOral cancerOral squamous cell carcinomaOSCCPDPNPodoplanin

Identifiers

PMID40681758
PMCPMC12274232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.